Abstract 204P
Background
Exploring the interaction between tissue and circulating immune descriptors may represent a critical step in our understanding of cancer immunity cycle to dissect distinct immunotherapy (IO) outcomes. Thus, we determined whether a comprehensive immune profiling, including tumor immune microenviroment (TIME) and peripheral blood (PB) might offer an “holistic” view of patient-specific immune background, potentially leading to new personalized therapeutic strategies.
Methods
On 59 consecutive IO-treated NSCLC patients, digital microscopy was employed on tissue samples to assess densities and spatial distribution (intratumor and stromal) of different Tumor-infiltrating lymphocytes (TILs) subpopulations (CD3+, CD4+-CD8+, PD-1+); peripheral blood (PB) samples were analyzed by Flow cytometry and immunenzymatic assay to determine circulating immune-inflammatory features. Statistical analyses were conducted to assess potential correlations between TIME and blood immune features.
Results
In our cohort of NSCLC patients, PB analysis revealed a significant direct correlation between the density of total and intratumor CD3+ TILs and the percentage of circulating CD3+ T cells. Moreover, higher CD8+ TILs correlated with an increase in circulating CD8+Ki67+ and a decrease in immunosuppressive Tregs (P<0.05). Cytokine analysis showed that IL-6 direclty correlated with TILs density, while IL-1β, IL-12p70, and IL-2 were linked to CD8/CD3 ratios (P<0.05). An inverse relationship was observed between PD-1/CD8 ratio and IL-1β, IFN-γ and TGF-β1, along with a negative correlation between IL-4 and PD-1+ TILs (P<0.05). Additionally, we found that PD-L1neg patients displayed higher levels of blood monocytes and Tregs. Increased PD-L1 expression correlated with higher CD3+ TILs, and a significant inverse relationship was noted between PD-L1 levels and the PD1-to-CD8 TILs ratio, suggesting that PD-L1+ cancer cells may inhibit cytotoxic T cells.
Conclusions
Our findings strongly suggest the existence of a complex crosstalk between tissue and circulating compartments in shaping the immune response against the tumor and likely the proneness to benefit from immunotherapy in advanced NSCLC patients.
Legal entity responsible for the study
University Hospital of Parma.
Funding
AIRC Associazione Italiana Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract